Clinical Trial

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 27, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-04; most recent amendment 2024-09-25.
Status change: Not Yet Recruiting → Recruiting 2024-01-10
Trial Details
NCT Number NCT05988216
Lead Sponsor Bioray Laboratories
Collaborators: First Affiliated Hospital of Zhejiang University
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 12 participants
Start Date 2023-08-14
Primary Completion 2024-12 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-09-27